Transgene Biotek Ltd — Board Meeting, 07-05-2025: Board Meeting

Transgene Biotek has announced a board meeting on which audited financial results for the quarter and half-year were taken on record. The company reported total income of Rs. 104.42 lakhs for the year, with expenses rising to Rs. 172.03 lakhs, leading to a net loss of Rs. 67.61 lakhs and a basic EPS of Rs. (0.09). The auditors issued an unmodified opinion on both standalone and consolidated results. Cash flow improved with operating cash inflows of Rs. 119.58 lakhs, supported by secured debt raised to clear dues to BIRAC. Oral insulin human clinical studies are progressing without side effects. The company faces a Rs. 203.02 Cr penalty from the Enforcement Directorate related to GDR issues, currently under appeal at the Appellate Tribunal; the hearing was adjourned. Subsidiary Transgene Biotek HK Ltd remains non-operational with no transactions. No investor complaints were received during the quarter.